Patent · US Active

TG2 inhibitor piperazine compounds and uses thereof

US10894777B2 · kind B2 · utility

0Cited by

0References

12Claims

0Family size

Assignees

THE UNIVERSITY OF OTTAWA · CA
UNIVERSITY OF MARYLAND, BALTIMORE · US
University of Rochester · US

Inventors

Jeffrey Keillor · Montréal, CA
Abdullah Farhad Akbar · Ottawa, CA
Richard L. Eckert · Cambridge, US
Matthew Joseph Fisher · Mooresville, US
Gail V. W. Johnson · Rochester, US

Key dates

Filing date	Apr 13, 2017
Grant date	Jan 19, 2021
Priority date	—
Expiry date	May 16, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D405/12
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

There are provided Tissue Transglutaminase (TG2) inhibitor compounds, and compositions and methods of use thereof for the prevention or treatment of a cancer. Compounds of Formula I, and pharmaceutically acceptable salts thereof, are provided:

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.